383 related articles for article (PubMed ID: 16293576)
1. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
3. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone.
Naot D; Bava U; Matthews B; Callon KE; Gamble GD; Black M; Song S; Pitto RP; Cundy T; Cornish J; Reid IR
J Bone Miner Res; 2007 Feb; 22(2):298-309. PubMed ID: 17129176
[TBL] [Abstract][Full Text] [Related]
4. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
6. Endogenous bone morphogenetic proteins in human bone marrow-derived multipotent mesenchymal stromal cells.
Seib FP; Franke M; Jing D; Werner C; Bornhäuser M
Eur J Cell Biol; 2009 May; 88(5):257-71. PubMed ID: 19303661
[TBL] [Abstract][Full Text] [Related]
7. Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model.
Hong X; Miller C; Savant-Bhonsale S; Kalkanis SN
Neurosurgery; 2009 Jun; 64(6):1139-46; discussion 1146-7. PubMed ID: 19487894
[TBL] [Abstract][Full Text] [Related]
8. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma.
Liu S; Ishikawa H; Li FJ; Ma Z; Otsuyama K; Asaoku H; Abroun S; Zheng X; Tsuyama N; Obata M; Kawano MM
Cancer Res; 2005 Mar; 65(6):2269-76. PubMed ID: 15781640
[TBL] [Abstract][Full Text] [Related]
9. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Fritz V; Noël D; Bouquet C; Opolon P; Voide R; Apparailly F; Louis-Plence P; Bouffi C; Drissi H; Xie C; Perricaudet M; Müller R; Schwarz E; Jorgensen C
Stem Cells; 2008 Nov; 26(11):2981-90. PubMed ID: 18757301
[TBL] [Abstract][Full Text] [Related]
10. How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow.
Gregory CA; Gunn WG; Reyes E; Smolarz AJ; Munoz J; Spees JL; Prockop DJ
Ann N Y Acad Sci; 2005 May; 1049():97-106. PubMed ID: 15965110
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.
Xu S; Menu E; De Becker A; Van Camp B; Vanderkerken K; Van Riet I
Stem Cells; 2012 Feb; 30(2):266-79. PubMed ID: 22102554
[TBL] [Abstract][Full Text] [Related]
12. [Both myeloma cells and bone marrow stromal cells are involved in the overproduction of interleukin 6 in multiple myeloma].
Ding S; Hou J; Sun A
Zhonghua Xue Ye Xue Za Zhi; 1998 Jun; 19(6):306-8. PubMed ID: 11243111
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression.
Potier E; Ferreira E; Andriamanalijaona R; Pujol JP; Oudina K; Logeart-Avramoglou D; Petite H
Bone; 2007 Apr; 40(4):1078-87. PubMed ID: 17276151
[TBL] [Abstract][Full Text] [Related]
14. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells.
Menon LG; Picinich S; Koneru R; Gao H; Lin SY; Koneru M; Mayer-Kuckuk P; Glod J; Banerjee D
Stem Cells; 2007 Feb; 25(2):520-8. PubMed ID: 17053212
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis.
Hung SC; Pochampally RR; Chen SC; Hsu SC; Prockop DJ
Stem Cells; 2007 Sep; 25(9):2363-70. PubMed ID: 17540857
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fetal and adult marrow stromal cells in osteogenesis with and without glucocorticoids.
Chang PL; Blair HC; Zhao X; Chien YW; Chen D; Tilden AB; Chang Z; Cao X; Faye-Petersen OM; Hicks P
Connect Tissue Res; 2006; 47(2):67-76. PubMed ID: 16754512
[TBL] [Abstract][Full Text] [Related]
17. The influence of proepicardial cells on the osteogenic potential of marrow stromal cells in a three-dimensional tubular scaffold.
Valarmathi MT; Yost MJ; Goodwin RL; Potts JD
Biomaterials; 2008 May; 29(14):2203-16. PubMed ID: 18289664
[TBL] [Abstract][Full Text] [Related]
18. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
19. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
20. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.
Giuliani N; Mangoni M; Rizzoli V
Exp Hematol; 2009 Aug; 37(8):879-86. PubMed ID: 19446662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
